Triple

T23417458
Position Surface form Disambiguated ID Type / Status
Subject Bristol Myers Squibb E560549 entity
Predicate product P490 FINISHED
Object Sprycel — NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Sprycel | Statement: [Bristol Myers Squibb, product, Sprycel]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Sprycel
Context triple: [Bristol Myers Squibb, product, Sprycel]
  • A. Gleevec
    Gleevec is a groundbreaking targeted cancer therapy, best known for treating chronic myeloid leukemia by inhibiting the BCR-ABL tyrosine kinase.
  • B. Tasigna
    Tasigna is a prescription tyrosine kinase inhibitor used primarily to treat certain types of Philadelphia chromosome–positive chronic myeloid leukemia (CML) in adults and children.
  • C. Iclusig
    Iclusig is a cancer medication containing ponatinib, primarily used to treat certain types of leukemia such as chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
  • D. Venclexta
    Venclexta is a targeted cancer therapy (venetoclax) used primarily to treat certain types of leukemia by inhibiting the BCL-2 protein that helps cancer cells survive.
  • E. Imbruvica
    Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: Sprycel
Target entity description: Sprycel is a prescription cancer medication (dasatinib) used primarily to treat certain types of leukemia, including chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
  • A. Gleevec
    Gleevec is a groundbreaking targeted cancer therapy, best known for treating chronic myeloid leukemia by inhibiting the BCR-ABL tyrosine kinase.
  • B. Tasigna
    Tasigna is a prescription tyrosine kinase inhibitor used primarily to treat certain types of Philadelphia chromosome–positive chronic myeloid leukemia (CML) in adults and children.
  • C. Iclusig
    Iclusig is a cancer medication containing ponatinib, primarily used to treat certain types of leukemia such as chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
  • D. Venclexta
    Venclexta is a targeted cancer therapy (venetoclax) used primarily to treat certain types of leukemia by inhibiting the BCL-2 protein that helps cancer cells survive.
  • E. Imbruvica
    Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
  • F. None of above. chosen

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e2454cb1108190ab21ada5411a7146 completed April 17, 2026, 2:35 p.m.
NER Named-entity recognition batch_69f1a516d158819081e9710b4e372a21 completed April 29, 2026, 6:28 a.m.
Created at: April 17, 2026, 5:39 p.m.